The Department of Haematology offers numerous clinical trials for both blood cancers and non-cancerous blood disorders. We are one of the largest haematology trial centers in the region and well supported by the hospital's Clinical Trials and Research Centre.
Clinical trials are required to prove that new medications are safe and effective for people. Without clinical trials, new treatment options will not be approved for use. It is through them that we can possess the knowledge we have today and the potential to expand treatment options to manage diseases more effectively in the future.
As an integral part of our haematology clinical service, clinical trials allows us to offer up-to-date and novel therapies for our patients. Participating in a clinical trial will provide patients with the opportunity to contribute to furthering medical research and potentially benefit from new treatment options.
We have listed the current clinical trials available at SGH.
Do discuss with your doctor if you are considering in volunteering to be part of a clinical trial.
Chronic Myeloid Leukemia (CML)
PRospective study of Imatinb discontinuation in CML patients with a sustained complete Molecular response
Chronic Myeloid Leukemia (CML)
A phase III, multi-center, open-label, randomized study of oral asciminib versus Investigator selected TKI in patients with newly diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase
A Phase 3, Open-Label, Multicenter, Randomized, Active-controlled Study to Assess Pharmacokinetics and Compare the Efficacy, Safety, and Tolerability of P1101 vs Anagrelide as Second Line Therapy for Essential Thrombocythemia
Myelodysplastic Syndrome (MDS)
A Phase Ib, multicenter, open-label platform study of select drug combinations in adult patients with lower risk (very low, low, or intermediate risk) myelodysplastic syndrome
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic myelomonocytic leukemia (CMML), Essential Thrombocythemia, Polycythemia Vera
A Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations
A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared with Pomalidomide and Dexamethasone in Subjects with t(11;14) Positive Relapsed or Refractory Multiple Myeloma
A Phase 2 Study to Assess the Clinical Activity and Safety of REGN1979, an anti-CD20 x anti-CD3 Bispecific Antibody, in Patients with Previously Treated Diffuse Large B-cell Lymphoma or Follicular Lymphoma
A Phase 1/2 Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma
Diffuse Large B Cell Lymphoma
A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/ Refractory Diffuse Large B-cell Lymphoma
A phase I/Ib open-label, multi-center dose escalation study of JBH492 in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)
Chronic lymphocytic leukemia
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
A multicenter, single-arm, open-label trial to evaluate efficacy and safety of oral, twice daily LNP023 in adult PNH patients who are naïve to complement inhibitor therapy
A Phase III, Randomized, Open-Label, Active-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Not Previously Treated with Complement Inhibitors
Immune thrombocytopenic purpura (ITP)
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults and Adolescents with Persistent or Chronic Immune Thrombocytopenia (ITP)